{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:16:26Z","timestamp":1791908186808,"version":"4.3.4"},"reference-count":78,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.beem.2022.101679","type":"journal-article","created":{"date-parts":[[2022,5,26]],"date-time":"2022-05-26T23:13:14Z","timestamp":1653606794000},"page":"101679","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Innovative therapeutics in acromegaly"],"prefix":"10.1016","volume":"36","author":[{"given":"Leandro","family":"Kasuki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00f4nica R.","family":"Gadelha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.beem.2022.101679_bib1","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1210\/er.2018-00115","article-title":"Systemic complications of acromegaly and the impact of the current treatment landscape: an update","volume":"40","author":"Gadelha","year":"2019","journal-title":"Endocr Rev"},{"key":"10.1016\/j.beem.2022.101679_bib2","doi-asserted-by":"crossref","first-page":"630","DOI":"10.20945\/2359-3997000000193","article-title":"Determinants of morbidities and mortality in acromegaly","volume":"63","author":"Kasuki","year":"2019","journal-title":"Archives of Endocrinology and Metabolism"},{"key":"10.1016\/j.beem.2022.101679_bib3","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.ecl.2020.05.007","article-title":"Acromegaly: update on management and long-term morbidities","volume":"49","author":"Kasuki","year":"2020","journal-title":"Endocrinol Metabol Clin North America"},{"key":"10.1016\/j.beem.2022.101679_bib4","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s11154-020-09588-z","article-title":"Multidisciplinary management of acromegaly: a consensus","volume":"21","author":"Giustina","year":"2020","journal-title":"Rev Endocrol Metabol Disorders"},{"key":"10.1016\/j.beem.2022.101679_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11102-020-01091-7","article-title":"A\u00a0Pituitary Society update to acromegaly management guidelines","volume":"24","author":"Fleseriu","year":"2020","journal-title":"Pituitary"},{"key":"10.1016\/j.beem.2022.101679_bib6","doi-asserted-by":"crossref","first-page":"3933","DOI":"10.1210\/jc.2014-2700","article-title":"Acromegaly: an endocrine society clinical practice guideline","volume":"99","author":"Katznelson","year":"2014","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"key":"10.1016\/j.beem.2022.101679_bib7","doi-asserted-by":"crossref","first-page":"101264","DOI":"10.1016\/j.beem.2019.02.001","article-title":"National acromegaly registries","volume":"33","author":"Maione","year":"2019","journal-title":"Best Pract Res Clin Endocrinol Metabol"},{"key":"10.1016\/j.beem.2022.101679_bib8","first-page":"1","article-title":"New and emerging pharmacological treatment options for acromegaly","author":"Antunes","year":"2021","journal-title":"Expet Opin Pharmacother"},{"key":"10.1016\/j.beem.2022.101679_bib9","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s12020-018-1590-8","article-title":"Predictors of surgical outcome and early criteria of remission in acromegaly","volume":"60","author":"Antunes","year":"2018","journal-title":"Endocrine"},{"key":"10.1016\/j.beem.2022.101679_bib10","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1111\/j.1365-2265.2008.03441.x","article-title":"Octreotide LAR vs. surgery in newly diagnosed patients with acromegaly: a randomized, open-label, multicentre study","volume":"70","author":"Colao","year":"2009","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.beem.2022.101679_bib11","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/j.1365-2265.2007.02825.x","article-title":"A\u00a0prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly","volume":"66","author":"Mercado","year":"2007","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.beem.2022.101679_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/cen.12797","article-title":"A\u00a0paradigm shift in the medical treatment of acromegaly: from a 'trial and error' to a personalized therapeutic decision-making process","volume":"83","author":"Gadelha","year":"2015","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.beem.2022.101679_bib13","doi-asserted-by":"crossref","first-page":"1700391","DOI":"10.1183\/13993003.00391-2017","article-title":"What is precision medicine?","volume":"50","author":"Konig","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.beem.2022.101679_bib14","doi-asserted-by":"crossref","first-page":"R89","DOI":"10.1530\/EJE-17-1006","article-title":"Management OF endocrine disease: personalized medicine in the treatment of acromegaly","volume":"178","author":"Kasuki","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2022.101679_bib15","first-page":"dgab125","article-title":"Machine learning-based prediction model for treatment of acromegaly with first-generation somatostatin receptor ligands","author":"Wildemberg","year":"2021","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"key":"10.1016\/j.beem.2022.101679_bib16","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1210\/clinem\/dgab726","article-title":"The future of somatostatin receptor ligands in acromegaly","volume":"107","author":"Gadelha","year":"2022","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"key":"10.1016\/j.beem.2022.101679_bib17","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.tem.2012.11.007","article-title":"Novel pathway for somatostatin analogs in patients with acromegaly","volume":"24","author":"Gadelha","year":"2013","journal-title":"Trends Endocrinol Metabol"},{"key":"10.1016\/j.beem.2022.101679_bib18","doi-asserted-by":"crossref","first-page":"4857","DOI":"10.3390\/cancers13194857","article-title":"Gsp mutation is not a molecular biomarker of long-term response to first-generation somatostatin receptor ligands in acromegaly","volume":"13","author":"Wildemberg","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.beem.2022.101679_bib19","doi-asserted-by":"crossref","first-page":"dgaa387","DOI":"10.1210\/clinem\/dgaa387","article-title":"Multivariable prediction model for biochemical response to first-generation somatostatin receptor ligands in acromegaly","volume":"105","author":"Coopmans","year":"2020","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"key":"10.1016\/j.beem.2022.101679_bib20","doi-asserted-by":"crossref","first-page":"L25","DOI":"10.1530\/ERC-12-0020","article-title":"AIP expression in sporadic somatotropinomas is a predictor of the response to octreotide LAR therapy independent of SSTR2 expression","volume":"19","author":"Kasuki","year":"2012","journal-title":"Endocr Relat Canc"},{"key":"10.1016\/j.beem.2022.101679_bib21","doi-asserted-by":"crossref","first-page":"E1730","DOI":"10.1210\/jc.2013-2145","article-title":"Expression of SSTR2a, but not of SSTRs 1, 3, or 5 in somatotroph adenomas assessed by monoclonal antibodies was reduced by octreotide and correlated with the acute and long-term effects of octreotide","volume":"98","author":"Casar-Borota","year":"2013","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"key":"10.1016\/j.beem.2022.101679_bib22","doi-asserted-by":"crossref","first-page":"E66","DOI":"10.1210\/jc.2012-2609","article-title":"Immunoreactivity score using an anti-sst2A receptor monoclonal antibody strongly predicts the biochemical response to adjuvant treatment with somatostatin analogs in acromegaly","volume":"98","author":"Gatto","year":"2013","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"key":"10.1016\/j.beem.2022.101679_bib23","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1530\/EJE-07-0562","article-title":"Quantitative analysis of somatostatin receptor subtypes (1-5) gene expression levels in somatotropinomas and correlation to in\u00a0vivo hormonal and tumor volume responses to treatment with octreotide LAR","volume":"158","author":"Taboada","year":"2008","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2022.101679_bib24","first-page":"580","article-title":"Validation of immunohistochemistry for somatostatin receptor subtype 2A in human somatotropinomas: comparison between quantitative real time RT-PCR and immunohistochemistry","volume":"35","author":"Wildemberg","year":"2012","journal-title":"J\u00a0Endocrinol Invest"},{"key":"10.1016\/j.beem.2022.101679_bib25","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/j.1365-2265.2011.04163.x","article-title":"Adenoma granulation pattern correlates with clinical variables and effect of somatostatin analogue treatment in a large series of patients with acromegaly","volume":"76","author":"Fougner","year":"2012","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.beem.2022.101679_bib26","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s12022-008-9029-z","article-title":"Clinicopathological features of growth hormone-producing pituitary adenomas: difference among various types defined by cytokeratin distribution pattern including a transitional form","volume":"19","author":"Obari","year":"2008","journal-title":"Endocr Pathol"},{"key":"10.1016\/j.beem.2022.101679_bib27","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.1365-2265.2011.04286.x","article-title":"Intensity of pituitary adenoma on T2-weighted magnetic resonance imaging predicts the response to octreotide treatment in newly diagnosed acromegaly","volume":"77","author":"Heck","year":"2012","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.beem.2022.101679_bib28","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s12020-015-0766-8","article-title":"Quantitative analyses of T2-weighted MRI as a potential marker for response to somatostatin analogs in newly diagnosed acromegaly","volume":"52","author":"Heck","year":"2016","journal-title":"Endocrine"},{"key":"10.1016\/j.beem.2022.101679_bib29","doi-asserted-by":"crossref","first-page":"E373","DOI":"10.1210\/jc.2009-2556","article-title":"Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: an international collaborative study","volume":"95","author":"Daly","year":"2010","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"key":"10.1016\/j.beem.2022.101679_bib30","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1210\/jc.2009-2197","article-title":"The expression of E-cadherin in somatotroph pituitary adenomas is related to tumor size, invasiveness, and somatostatin analog response","volume":"95","author":"Fougner","year":"2010","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"key":"10.1016\/j.beem.2022.101679_bib31","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1080\/00313020701329914","article-title":"The role of epithelial-mesenchymal transition in cancer pathology","volume":"39","author":"Guarino","year":"2007","journal-title":"Pathology"},{"key":"10.1016\/j.beem.2022.101679_bib32","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1530\/ERC-18-0565","article-title":"Molecular profiling for acromegaly treatment: a validation study","volume":"27","author":"Puig-Domingo","year":"2020","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.beem.2022.101679_bib33","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/cen.12731","article-title":"Treatment of acromegaly in the era of personalized and predictive medicine","volume":"83","author":"Puig Domingo","year":"2015","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.beem.2022.101679_bib34","doi-asserted-by":"crossref","first-page":"169","DOI":"10.23736\/S0391-1977.18.02937-1","article-title":"Precision medicine in the treatment of acromegaly","volume":"44","author":"Puig-Domingo","year":"2019","journal-title":"Minerva Endocrinol"},{"key":"10.1016\/j.beem.2022.101679_bib35","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1530\/EJE-13-0349","article-title":"Ki-67 is a predictor of acromegaly control with octreotide LAR independent of SSTR2 status and relates to cytokeratin pattern","volume":"169","author":"Kasuki","year":"2013","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2022.101679_bib36","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.canlet.2015.01.037","article-title":"Truncated somatostatin receptor variant sst5TMD4 confers aggressive features (proliferation, invasion and reduced octreotide response) to somatotropinomas","volume":"359","author":"Luque","year":"2015","journal-title":"Cancer Lett"},{"key":"10.1016\/j.beem.2022.101679_bib37","doi-asserted-by":"crossref","first-page":"206","DOI":"10.3803\/EnM.2020.35.2.206","article-title":"Precision therapy in acromegaly caused by pituitary tumors: how close is it to reality?","volume":"35","author":"Ku","year":"2020","journal-title":"Endocrinol and Metabol (Seoul)"},{"key":"10.1016\/j.beem.2022.101679_bib38","doi-asserted-by":"crossref","DOI":"10.1007\/s11102-022-01216-0","article-title":"Machine learning as a clinical decision support tool for patients with acromegaly","author":"Sulu","year":"2022","journal-title":"Pituitary"},{"key":"10.1016\/j.beem.2022.101679_bib39","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1517\/14656566.2016.1146688","article-title":"Pasireotide for the treatment of acromegaly","volume":"17","author":"Wildemberg","year":"2016","journal-title":"Expet Opin Pharmacother"},{"key":"10.1016\/j.beem.2022.101679_bib40","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1210\/jc.2013-2480","article-title":"Pasireotide versus octreotide in acromegaly: a head-to-head superiority study","volume":"99","author":"Colao","year":"2014","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"key":"10.1016\/j.beem.2022.101679_bib41","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S2213-8587(14)70169-X","article-title":"Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial","volume":"2","author":"Gadelha","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.beem.2022.101679_bib42","doi-asserted-by":"crossref","first-page":"648411","DOI":"10.3389\/fendo.2021.648411","article-title":"Pasireotide in the personalized treatment of acromegaly","volume":"12","author":"Puig-Domingo","year":"2021","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.beem.2022.101679_bib43","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1530\/EJE-19-0840","article-title":"T2-signal intensity, SSTR expression, and somatostatin analogs efficacy predict response to pasireotide in acromegaly","volume":"182","author":"Coopmans","year":"2020","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2022.101679_bib44","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1530\/EJE-15-0832","article-title":"Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: an immunohistochemical study","volume":"174","author":"Iacovazzo","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2022.101679_bib45","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1210\/jc.2018-01524","article-title":"Pasireotide responsiveness in acromegaly is mainly driven by somatostatin receptor subtype 2 expression","volume":"104","author":"Muhammad","year":"2019","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"key":"10.1016\/j.beem.2022.101679_bib46","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1530\/EJE-20-0767","article-title":"Pegvisomant and Pasireotide LAR as second line therapy in acromegaly: clinical effectiveness and predictors of response","volume":"184","author":"Chiloiro","year":"2021","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2022.101679_bib47","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1530\/EC-19-0004","article-title":"AIP-mutated acromegaly resistant to first-generation somatostatin analogs: long-term control with pasireotide LAR in two patients","volume":"8","author":"Daly","year":"2019","journal-title":"Endocrine Connections"},{"key":"10.1016\/j.beem.2022.101679_bib48","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1530\/EJE-18-0616","article-title":"Long-term treatment with pegvisomant: observations from 2090 acromegaly patients in ACROSTUDY","volume":"179","author":"Buchfelder","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2022.101679_bib49","first-page":"328","article-title":"Brazilian multicenter study on pegvisomant treatment in acromegaly","volume":"63","author":"Boguszewski","year":"2019","journal-title":"Archives of Endocrinol Metabol"},{"issue":"Suppl 2","key":"10.1016\/j.beem.2022.101679_bib50","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1530\/eje.0.148s021","article-title":"Discovery and mechanism of action of pegvisomant","volume":"148","author":"Kopchick","year":"2003","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2022.101679_bib51","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.eprac.2021.12.017","article-title":"Personalized medical treatment of patients with acromegaly: a review","volume":"28","author":"Lim","year":"2022","journal-title":"Endocr Pract"},{"key":"10.1016\/j.beem.2022.101679_bib52","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1590\/2359-3997000000210","article-title":"Experience with pegvisomant treatment in acromegaly in a single Brazilian tertiary reference center: efficacy, safety and predictors of response","volume":"60","author":"Kasuki","year":"2016","journal-title":"Archives of Endocrinol Metabol"},{"key":"10.1016\/j.beem.2022.101679_bib53","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1007\/s11102-015-0673-2","article-title":"Prediction of therapy response in acromegalic patients under pegvisomant therapy within the German ACROSTUDY cohort","volume":"18","author":"Sievers","year":"2015","journal-title":"Pituitary"},{"key":"10.1016\/j.beem.2022.101679_bib54","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1159\/000448844","article-title":"The effect of the exon-3-deleted growth hormone receptor on pegvisomant-treated acromegaly: a systematic review and meta-analysis","volume":"105","author":"Franck","year":"2017","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.beem.2022.101679_bib55","doi-asserted-by":"crossref","first-page":"R274","DOI":"10.1530\/EC-20-0433","article-title":"Novel therapies for acromegaly","volume":"9","author":"Maia","year":"2020","journal-title":"Endocrine Connections"},{"key":"10.1016\/j.beem.2022.101679_bib56","doi-asserted-by":"crossref","DOI":"10.1007\/s11102-020-01038-y","article-title":"An evaluation of the Acromegaly Treatment Satisfaction Questionnaire (Acro-TSQ) in adult patients with acromegaly, including correlations with other patient-reported outcome measures: data from two large multicenter international studies","author":"Fleseriu","year":"2020","journal-title":"Pituitary"},{"key":"10.1016\/j.beem.2022.101679_bib57","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s12902-020-00595-4","article-title":"Patient reported outcome data from acromegaly patients treated with injectable somatostatin receptor ligands (SRLs) in routine clinical practice","volume":"20","author":"Geer","year":"2020","journal-title":"BMC Endocr Disord"},{"key":"10.1016\/j.beem.2022.101679_bib58","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1210\/jc.2012-1179","article-title":"Oral octreotide absorption in human subjects: comparable pharmacokinetics to parenteral octreotide and effective growth hormone suppression","volume":"97","author":"Tuvia","year":"2012","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"key":"10.1016\/j.beem.2022.101679_bib59","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1007\/s11095-014-1303-9","article-title":"A\u00a0novel suspension formulation enhances intestinal absorption of macromolecules via transient and reversible transport mechanisms","volume":"31","author":"Tuvia","year":"2014","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.beem.2022.101679_bib60","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1210\/jc.2014-4113","article-title":"Safety and efficacy of oral octreotide in acromegaly: results of a multicenter phase III trial","volume":"100","author":"Melmed","year":"2015","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"key":"10.1016\/j.beem.2022.101679_bib61","doi-asserted-by":"crossref","first-page":"dgaa526","DOI":"10.1210\/clinem\/dgaa526","article-title":"Maintenance of acromegaly control in patients switching from injectable somatostatin receptor ligands to oral octreotide","volume":"105","author":"Samson","year":"2020","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"key":"10.1016\/j.beem.2022.101679_bib62","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/S2213-8587(21)00296-5","article-title":"Maintenance of response to oral octreotide compared with injectable somatostatin receptor ligands in patients with acromegaly: a phase 3, multicentre, randomised controlled trial","volume":"10","author":"Fleseriu","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.beem.2022.101679_bib63","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3389\/fendo.2018.00078","article-title":"Novel somatostatin receptor ligands therapies for acromegaly","volume":"9","author":"Paragliola","year":"2018","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.beem.2022.101679_bib64","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/bcp.12698","article-title":"Octreotide s.c. depot provides sustained octreotide bioavailability and similar IGF-1 suppression to octreotide LAR in healthy volunteers","volume":"80","author":"Tiberg","year":"2015","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.beem.2022.101679_bib65","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s00280-018-3734-1","article-title":"Octreotide SC depot in patients with acromegaly and functioning neuroendocrine tumors: a phase 2, multicenter study","volume":"83","author":"Pavel","year":"2019","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.beem.2022.101679_bib66","doi-asserted-by":"crossref","first-page":"A524","DOI":"10.1210\/jendso\/bvab048.1068","article-title":"Pharmacokinetics and safety of an improved oral formulation of paltusotine, a selective, non-peptide somatostatin receptor 2 (SST2) agonist for the treatment of acromegaly","volume":"5","author":"Luo","year":"2021","journal-title":"J\u00a0Endocrine Soc"},{"key":"10.1016\/j.beem.2022.101679_bib67","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1007\/s11102-021-01201-z","article-title":"Paltusotine, a novel oral once-daily nonpeptide SST2 receptor agonist, suppresses GH and IGF-1 in healthy volunteers","volume":"25","author":"Madan","year":"2022","journal-title":"Pituitary"},{"key":"10.1016\/j.beem.2022.101679_bib68","doi-asserted-by":"crossref","first-page":"A526","DOI":"10.1210\/jendso\/bvab048.1073","article-title":"Safety and efficacy of switching injected peptide long-acting somatostatin receptor ligands to once daily oral paltusotine: ACROBAT Edge phase 2 study","volume":"5","author":"Gadelha","year":"2021","journal-title":"J\u00a0Endocrine Soc"},{"key":"10.1016\/j.beem.2022.101679_bib70","first-page":"P80","article-title":"ACROBAT Advance: progress report on a study of long-term safety and efficacy of paltusotine for the treatment of acromegaly","volume":"77","author":"Randeva","year":"2021","journal-title":"Endocr Abstr"},{"key":"10.1016\/j.beem.2022.101679_bib71","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1210\/endo.142.1.7880","article-title":"Novel long-acting somatostatin analog with endocrine selectivity: potent suppression of growth hormone but not of insulin","volume":"142","author":"Afargan","year":"2001","journal-title":"Endocrinology"},{"key":"10.1016\/j.beem.2022.101679_bib72","first-page":"GP123","article-title":"A\u00a0placebo-controlled study to assess the dose-effect of COR-005, a novel somatostatin analogue on plasma glucose regulation compared to octreotide in healthy male subjects","volume":"41","author":"Kutz","year":"2016","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.beem.2022.101679_bib73","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/BF03347512","article-title":"PTR-3173 (somatoprim), a novel somatostatin analog with affinity for somatostatin receptors 2, 4 and 5 is a potent inhibitor of human GH secretion","volume":"27","author":"Shimon","year":"2004","journal-title":"J\u00a0Endocrinol Invest"},{"key":"10.1016\/j.beem.2022.101679_bib74","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1530\/EJE-11-0737","article-title":"DG3173 (somatoprim), a unique somatostatin receptor subtypes 2-, 4- and 5-selective analogue, effectively reduces GH secretion in human GH-secreting pituitary adenomas even in Octreotide non-responsive tumours","volume":"166","author":"Plockinger","year":"2012","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2022.101679_bib75","article-title":"Mon-464 non-clinical profiling of ONO-5788, a novel oral small molecule somatostatin receptor type-2 (SST2) agonist, to support studies in humans","volume":"3","author":"Komagata","year":"2019","journal-title":"J\u00a0Endocrine Soci"},{"key":"10.1016\/j.beem.2022.101679_bib76","article-title":"Mon-477 octreotide and ONO-ST-468, a novel and potent somatostatin receptor type-2 (SST2) agonist, suppress GH hypersecretion in the monkey","volume":"3","author":"Tanaka","year":"2019","journal-title":"J\u00a0Endocrine Soc"},{"key":"10.1016\/j.beem.2022.101679_bib77","article-title":"Mon-459 ONO-5788, a novel oral small molecule somatostatin receptor type-2 (SST2) agonist, attenuates GH hypersecretion in human GH-secreting, pituitary adenoma-derived cells","volume":"3","author":"Zhou","year":"2019","journal-title":"J\u00a0Endocrine Soc"},{"key":"10.1016\/j.beem.2022.101679_bib78","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.coph.2015.07.005","article-title":"An overview of the clinical application of antisense oligonucleotides for RNA-targeting therapies","volume":"24","author":"McClorey","year":"2015","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.beem.2022.101679_bib80","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1530\/EJE-18-0138","article-title":"A\u00a0randomised, open-label, parallel group phase 2 study of antisense oligonucleotide therapy in acromegaly","volume":"179","author":"Trainer","year":"2018","journal-title":"Eur J Endocrinol"}],"container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X22000665?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X22000665?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T16:59:39Z","timestamp":1761497979000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521690X22000665"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":78,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S1521690X22000665"],"URL":"https:\/\/doi.org\/10.1016\/j.beem.2022.101679","relation":{},"ISSN":["1521-690X"],"issn-type":[{"value":"1521-690X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Innovative therapeutics in acromegaly","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Endocrinology & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beem.2022.101679","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101679"}}